Category Archives: Patent

Switzerland wants stricter intellectual property rules in India that could harm generic drug makers

By Jyotsna Singh, Scroll | March 23, 2017 Developed countries continue to put pressure on India to move to stricter intellectual property regimes that would favour multinational pharmaceutical countries over generic drug manufacturers. A new leaked document shows that the … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Uncategorized | Leave a comment

European FTA pushes for tougher IPR rules under ongoing trade talks with India

Switzerland proposed that India agree to broader patentable principles, as per a leaked note on the proposed Intellectual Property Rights chapter of the talks   The leaked note followed a telephone conversation commerce minister Sitharaman and Swiss minister for economic … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, IPR, Patent, Uncategorized | Leave a comment

India–EFTA trade talks may make medicines more expensive

MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’   Geneva/New Delhi, 22March 2017 – Asintellectual property (IP) negotiators from India andthe four countries from EFTA (European Free Trade Association) meeting New Delhi … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, Evergreening, Patent, Sec 3 (d), Uncategorized | Leave a comment

In India’s Fight Against Tuberculosis, Diagnostics Remains Poorly Understood

A lack of innovation in diagnostics is making Indians more prone to drug-resistant TB, which is difficult to treat and could be fatal. By Ankur Paliwal, The Wire | March 3, 2017 The end of an otherwise typical day in the winter of … Continue reading

Posted in Innovation, Patent, Uncategorized | Tagged | Leave a comment

RCEP and Health: This Kind of ‘Progress’ is Not What India and the World Need

Source: The Wire Concerns remain over the impact of RCEP negotiations on public health and access to medicines Negotiators from 16 countries are meeting in Kobe, Japan on Monday to begin the 17th round of negotiations of the Regional Comprehensive Economic … Continue reading

Posted in Data Exclusivity, Investor state dispute, IPR, Patent, Patent Term Extension, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Civil society, patient groups call on Japan and South Korea to withdraw harmful proposals from RCEP negotiations

By Ramesh Shankar, http://www.pharmabiz.com | February 24, 2017 As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet next week in Kobe, Japan, for the seventeenth round of negotiations, civil society and patient groups, including the international medical humanitarian … Continue reading

Posted in Data Exclusivity, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

Pharma PSUs Are Not Ready To Die!

By Murali Neelakantan, BloombergQuintOpinion | February 7, 2017 The government’s decision to explore the strategic sale of Indian Drugs and Pharmaceuticals Ltd. and Bengal Chemicals – even as questions were asked of the move last week by parliamentarians including those from the BJP … Continue reading

Posted in Generics, Patent, Pricing, Uncategorized | Leave a comment